Abstract for presentation at 11th International Congress of Human Genetics

MTHFR C677T polymorphism and elevation of transaminases in Mexican patients with Rheumatoid Arthritis treated with methotrexate

  • Juan Mena, Doctorado en Genetica Humana, IGH, U de G; Division de Genetica CIBO, IMSS, Mexico
  • PhD MD Ingrid Davalos, Division de Genetica, CIBO, IMSS, Doctorado en Genetica Humana, IGH, U de G,, Mexico
  • Dr David Banuelos, Division de Investigacion, UMAE, HE, CMNO, Mexico
  • Dr Julia Sanchez, Division de Investigacion, UMAE, HE, CMNO, Mexico
  • Dr Lucila Sandoval, Division de Genetica, CIBO, IMSS, Doctorado en Genetica Humana, IGH, U de G, Mexico
  • Dr Laura Gonzalez-Lopez, Division de Investigacion, UMAE, HE, CMNO, Mexico
  • Dr Jorge Gamez-Nava, Division de Investigacion, UMAE, HE, CMNO, Mexico
  • Dr Mario Salazar-Paramo, Division de Investigacion, UMAE, HE, CMNO, Mexico

    • Introduction: The variant C677T in the 5, 10-methylenetetrahydrofolate reductase (MTHFR) gene, has been involved in homocysteine metabolism and considered as a genetic risk factor in the increase of transaminases levels in patients with rheumatoid arthritis (RA) treated with methotrexate (MTX).
    Objective: To determine the MTHFR C677T genotype in patients with RA treated with MTX and their association with the increase in the serum levels of transaminases.
    Patients/Methods: In a cross–sectional study we included 71 patients with RA (ACR 1987) treated with MTX. Demographic, clinical, laboratory and therapeutic data were obtained using a estructured questionnaire. Molecular analysis was performed using PCR/RFLP HinfI technique. For statistical analysis, chi square test and OR were used.
    Results: From 71 patients 13 (18%) had an increase in the transaminases levels. The genotype frequencies -GF- (n, %) in the total group of patients were: CC (20, 28%), CT (38, 54%), TT (13, 18%); and the allelic frequencies -AF- were: for C (78, 55%) and T (64, 45%). The GF in the RA-MTX subgroup without elevation in the transaminases were: CC (18, 31%) CT (30, 52%) TT (10, 17%). The AF in this group were for C (66, 57%) and T (50, 43%). The GF among the RA-MTX subgroup with increased transaminases were: CC (3, 23%) CT (8, 62%) TT (2, 15%) with AF, C (14, 54%) and T (12, 46%). The T allele was more frequent in patients with RA-MTX and elevation of the transminases (46 vs 43).
    Conclusion: In subjects with RA treated with MTX the identification of MTHFR genotypes CT or TT, could be useful as a risk predictor of the elevation of transaminases.

    Conference Organiser - ICMS Pty Ltd